20 articles
A systematic review of 13 studies finds semaglutide and liraglutide meaningfully cut BMI and improve blood sugar in children and adolescents.
A new meta-analysis of 37,393 patients finds GLP-1 receptor agonists may reduce mortality and major cardiac events in type 2 diabetics with prior MI.
A new review argues that combining GLP-1 receptor agonists with structured exercise and dietary support preserves muscle and delivers lasting fat loss.
A Cochrane review of 37 RCTs finds obesity drugs modestly reduce weight in adolescents, but evidence quality is low and long-term data are absent.
GLP-1 receptor agonists show early promise for co-occurring substance use and mood disorders by targeting shared brain reward pathways.
A new review maps how tirzepatide's dual GIP/GLP-1 action reshapes metabolism across the pancreas, liver, gut, heart, kidneys, and brain.
Semaglutide and liraglutide show promise for dry eye and corneal repair, but may cause periocular volume loss that affects blinking and tear distribution.
With 225+ clinical trials behind it, intermittent fasting rivals calorie restriction for type 2 diabetes — yet major guidelines still ignore it.
A major review repositions type 2 diabetes as a proteinopathy, with amylin aggregation bridging metabolic decline and neurodegeneration.
A new framework reveals how lactate and β-hydroxybutyrate team up across organs to regulate metabolism, mitochondria, and disease.
Longevity experts endorse short CGM trials for non-diabetics, but RCT evidence remains thin. Here's what the data actually shows.
Dexcom G7 tops expert picks for metabolic biohacking, but evidence for non-diabetics remains mixed. Here's what the data says.
Expert reviews compare top CGMs for longevity use, but evidence for healthy adults remains limited. Here's what you need to know.
Top longevity doctors endorse CGMs for healthy adults, but evidence is mixed. Here's what the 2026 device reviews reveal.
Continuous glucose monitors are popular in biohacking circles, but direct evidence linking CGM use to extended lifespan remains thin.
Longevity experts endorse CGMs for metabolic optimization, but RCT evidence in non-diabetics is still thin.
Expert reviews of top CGM platforms reveal genuine metabolic insights — but no proof they extend lifespan in healthy adults.
A head-to-head review of 10 CGM devices for healthy adults, weighing real-world accuracy data against limited longevity evidence.
A meta-analysis of 4,941 adults finds FTO risk-allele carriers have higher triglycerides on calorie-restricted diets, but most metabolic markers respond similarly across genotypes.
A Cochrane review of two RCTs finds very low-certainty evidence that IGF-1 neither prevents nor worsens retinopathy of prematurity in extremely preterm infants.
